GH Research (NASDAQ:GHRS) Trading Down 0.5%

GH Research PLC (NASDAQ:GHRS)’s stock price was down 0.5% during trading on Thursday . The stock traded as low as $10.92 and last traded at $11.00. Approximately 80,609 shares were traded during mid-day trading, a decline of 42% from the average daily volume of 138,353 shares. The stock had previously closed at $11.05.

Analysts Set New Price Targets

Several equities analysts have commented on GHRS shares. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of GH Research in a research note on Monday, March 4th. JMP Securities lowered their target price on shares of GH Research from $50.00 to $39.00 and set a “market outperform” rating for the company in a research note on Friday, March 1st.

GH Research Price Performance

The business’s 50 day moving average is $9.32 and its 200 day moving average is $7.79. The stock has a market cap of $572.33 million, a price-to-earnings ratio of -16.18 and a beta of 0.84.

GH Research (NASDAQ:GHRS) last issued its earnings results on Thursday, February 29th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). As a group, analysts forecast that GH Research PLC will post -0.96 earnings per share for the current year.

Hedge Funds Weigh In On GH Research

Several large investors have recently bought and sold shares of GHRS. RTW Investments LP boosted its stake in GH Research by 53.4% in the third quarter. RTW Investments LP now owns 3,327,129 shares of the company’s stock valued at $33,438,000 after acquiring an additional 1,158,172 shares in the last quarter. BVF Inc. IL boosted its stake in GH Research by 12.1% in the fourth quarter. BVF Inc. IL now owns 10,400,158 shares of the company’s stock valued at $60,321,000 after acquiring an additional 1,125,000 shares in the last quarter. Lynx1 Capital Management LP boosted its stake in GH Research by 13.8% in the third quarter. Lynx1 Capital Management LP now owns 1,103,178 shares of the company’s stock valued at $11,087,000 after acquiring an additional 133,804 shares in the last quarter. Millennium Management LLC boosted its stake in GH Research by 585.8% in the fourth quarter. Millennium Management LLC now owns 69,339 shares of the company’s stock valued at $671,000 after acquiring an additional 59,228 shares in the last quarter. Finally, Morgan Stanley boosted its stake in GH Research by 7.1% in the fourth quarter. Morgan Stanley now owns 524,115 shares of the company’s stock valued at $5,094,000 after acquiring an additional 34,779 shares in the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

About GH Research

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD.